Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Prebet T, Etienne A, Devillier R, Romeo E, Charbonnier A, D'incan E, Esterni B, Arnoulet C, Blaise D, Vey N. Prebet T, et al. Among authors: etienne a. Cancer. 2011 Mar 1;117(5):974-81. doi: 10.1002/cncr.25554. Epub 2010 Oct 18. Cancer. 2011. PMID: 20957721 Free article.
Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R, Harbi S, Fürst S, Crocchiolo R, El-Cheikh J, Castagna L, Etienne A, Calmels B, Lemarie C, Prebet T, Granata A, Charbonnier A, Rey J, Chabannon C, Faucher C, Vey N, Blaise D. Devillier R, et al. Among authors: etienne a. Biol Blood Marrow Transplant. 2014 Oct;20(10):1560-5. doi: 10.1016/j.bbmt.2014.06.006. Epub 2014 Jun 14. Biol Blood Marrow Transplant. 2014. PMID: 24933658 Free article.
Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.
Devillier R, Bertoli S, Prébet T, Huguet F, Etienne A, Charbonnier A, Rey J, Delabesse E, D'Incan E, Huynh A, Blaise D, Récher C, Vey N. Devillier R, et al. Among authors: etienne a. Am J Hematol. 2015 Feb;90(2):E29-30. doi: 10.1002/ajh.23884. Epub 2014 Nov 19. Am J Hematol. 2015. PMID: 25363834 Free article. No abstract available.
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
Devillier R, Crocchiolo R, Castagna L, Fürst S, El Cheikh J, Faucher C, Prebet T, Etienne A, Chabannon C, Vey N, Esterni B, Blaise D. Devillier R, et al. Among authors: etienne a. Bone Marrow Transplant. 2012 May;47(5):639-45. doi: 10.1038/bmt.2012.3. Epub 2012 Feb 6. Bone Marrow Transplant. 2012. PMID: 22307016
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.
Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson D, Dombret H, Olive D. Vey N, et al. Among authors: etienne a. Blood. 2012 Nov 22;120(22):4317-23. doi: 10.1182/blood-2012-06-437558. Epub 2012 Sep 21. Blood. 2012. PMID: 23002117 Free article. Clinical Trial.
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Devillier R, Fürst S, Crocchiolo R, El-Cheikh J, Castagna L, Harbi S, Granata A, D'Incan E, Coso D, Chabannon C, Picard C, Etienne A, Calmels B, Schiano JM, Lemarie C, Stoppa AM, Bouabdallah R, Vey N, Blaise D. Devillier R, et al. Among authors: etienne a. Am J Hematol. 2014 Jan;89(1):83-7. doi: 10.1002/ajh.23592. Am J Hematol. 2014. PMID: 24108528 Free article.
292 results